Virtual Patients for Dose Selection: Enhancing Precision in Clinical Decision-Making

Abstract

Virtual patients (VPs) represent a transformative innovation in contemporary medicine, offering advanced simulation tools to optimize dose selection for diverse patient populations. By leveraging computational modeling, artificial intelligence, and real-world data, VPs enable personalized predictions of drug response and toxicity. This review synthesizes current evidence on the use of virtual patients for dose selection, discussing their epidemiological significance, underlying mechanisms, risk factors addressed, clinical features replicated, diagnostic integration, therapeutic applications, recent advances, and guideline recommendations. The article aims to provide clinicians and healthcare professionals with an in-depth understanding of how VPs can refine dosing strategies, reduce adverse events, and support precision medicine initiatives in routine practice.

Introduction

Precision medicine increasingly demands individualized therapeutic strategies, particularly in dose selection, to optimize efficacy and minimize toxicity. Traditional methods relying on population averages often overlook interpatient variability caused by genetics, comorbidities, and environmental influences. Virtual patients, constructed through computational models and patient-specific data, offer a dynamic platform to simulate pharmacokinetic and pharmacodynamic responses. Their integration into clinical workflows promises to bridge the gap between clinical trials and real-world populations, improving the safety and effectiveness of pharmaceutical interventions. This review explores the scientific foundations and clinical applications of virtual patients in dose selection, highlighting their role in advancing personalized healthcare.

Epidemiology / Disease Burden

Mismatched dosing contributes substantially to adverse drug reactions (ADRs), hospitalizations, and healthcare costs worldwide. Studies estimate that over 7% of hospitalized patients experience ADRs, with inappropriate dosing being a leading cause. The burden is particularly pronounced in vulnerable groups, such as pediatric, geriatric, and polypharmacy populations, where physiological heterogeneity complicates standardized dosing. The growing diversity in global populations and increasing prevalence of chronic diseases further amplify the need for individualized dose optimization. Virtual patient technologies are positioned to address these epidemiological challenges by enabling tailored dose selection across diverse cohorts.

Pathophysiology

The pathophysiology of variable drug response is multifactorial, encompassing genetic polymorphisms (e.g., CYP450 variants), organ dysfunction, altered protein binding, and drug-drug interactions. Virtual patient models integrate mechanistic representations of these factors—such as hepatic and renal clearance pathways, transporter activity, and receptor pharmacodynamics—into physiologically based pharmacokinetic (PBPK) and pharmacodynamic (PD) frameworks. By simulating how these mechanisms influence drug exposure and response, VPs can predict outcomes under various physiological and pathological conditions, facilitating dose optimization at the individual level.

Risk Factors

Virtual patient modeling addresses a spectrum of risk factors relevant to dose selection, including age, sex, body mass index, genetic background, organ function, and concomitant medications. Additional considerations include hepatic and renal impairment, comorbid diseases (e.g., diabetes, heart failure), and lifestyle factors such as diet and smoking. By simulating the impact of these variables, VPs help identify patients at increased risk for suboptimal response or toxicity, supporting safer and more effective dosing decisions.

Clinical Features

VP platforms replicate key clinical features relevant to drug dosing, such as variability in absorption, distribution, metabolism, and excretion (ADME). They can model both common and rare presentations, including pediatric or frail elderly populations, organ dysfunction, or genetic outliers. This enables clinicians to visualize likely patient trajectories under different dosing regimens, anticipate potential adverse effects, and optimize therapeutic windows. VPs can also be tailored to reflect real-world clinical scenarios, including polypharmacy and acute-on-chronic disease states, enhancing their utility in complex cases.

Diagnosis

Accurate diagnosis is foundational to effective dose selection. Virtual patient systems can integrate diagnostic data—such as laboratory values, imaging, and genomic information—into their simulations, refining the prediction of pharmacological response. For example, genotype-guided dosing in anticoagulation or oncology can be modeled using VPs to anticipate therapeutic and adverse outcomes, guiding diagnostic workup and dose titration. Integration with electronic health records (EHRs) further enables real-time, data-driven decision support at the point of care.

Treatment & Management

Traditional dose selection relies on standardized algorithms or empirical titration, which may not account for interindividual differences. Virtual patient models enable simulation of multiple dosing strategies, rapidly identifying optimal regimens for efficacy and safety. This is especially valuable in high-risk drugs with narrow therapeutic indices, such as warfarin, chemotherapeutics, or immunosuppressants. VPs also facilitate dose adjustment in special populations (e.g., pediatrics, pregnancy, renal impairment) and support therapeutic drug monitoring by predicting time-concentration profiles, informing real-time clinical management.

Recent Advances / Emerging Therapies

Recent technological advances have significantly enhanced the realism and predictive accuracy of virtual patient models. Machine learning and artificial intelligence are increasingly used to personalize simulations based on large-scale clinical and genomic datasets. Regulatory agencies, such as the FDA and EMA, now accept in silico data—including virtual clinical trials—for drug development and approval processes. Integration with wearable devices and digital biomarkers further allows dynamic updating of VP models, supporting adaptive dosing in chronic disease management. Emerging therapies, particularly in oncology and rare diseases, benefit from VP-based trial simulations to optimize dosing in populations where traditional trials are challenging.

Guideline Recommendations

Professional societies and regulatory bodies increasingly recognize the value of virtual patient models in dose selection. The FDA encourages model-informed drug development (MIDD), including the use of PBPK modeling for regulatory submissions. Clinical pharmacology guidelines recommend incorporating VP simulations, especially for special populations and drugs with complex pharmacokinetics. Ongoing efforts aim to standardize VP methodologies, validate model predictions with real-world data, and integrate VP tools into clinical decision support systems to facilitate guideline-concordant, individualized dosing.

Conclusion

Virtual patients are poised to revolutionize dose selection by enabling precision, safety, and efficiency in therapeutic decision-making. Their ability to model individual patient characteristics, anticipate pharmacological responses, and simulate real-world clinical scenarios makes them invaluable in modern medicine. As evidence and regulatory acceptance grow, integration of VP technologies into routine clinical practice will drive forward the goals of personalized medicine, minimizing adverse events and optimizing outcomes for diverse patient populations.